|
25 Jan 2021 |
Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa
|
|
25 Jan 2021 |
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease
|
|
25 Jan 2021 |
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates
|
|
25 Jan 2021 |
European Commission Approves BAVENCIO® (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
|
|
25 Jan 2021 |
Calquence met primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukaemia
|
|
25 Jan 2021 |
Genentech’s Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration
|
|
24 Jan 2021 |
Announcing Marketing Approval for Hunterase ICV Injection 15 mg, the World’s First Enzyme Replacement Therapy for Mucopolysaccharidosis Type II (Hunter Syndrome) Administered by ICV Injection
|
|
24 Jan 2021 |
Vaxess Technologies Awarded NSF and DARPA Funding for Development of mRNA-Based Single-Dose, Refrigeration-Free Vaccine Patch
|
|
24 Jan 2021 |
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
|
|
24 Jan 2021 |
FDA Approves Aurinia Pharmaceuticals’ LUPKYNIS™ (voclosporin) for Adult Patients with Active Lupus Nephritis
|
|
22 Jan 2021 |
Ulcerative Colitis Phase II Study of GSK2831781 Discontinued
|
|
22 Jan 2021 |
ViiV Healthcare announces FDA approval of Cabenuva (cabotegravir, rilpivirine), the first and only complete long-acting regimen for HIV treatment
|
|
22 Jan 2021 |
Incyte Announces Acceptance and Priority Review of BLA for Retifanlimab as a Potential Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
|
|
22 Jan 2021 |
YESCARTA® Approved in Japan for Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphomas
|
|
21 Jan 2021 |
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes
|
|
21 Jan 2021 |
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
|
|
21 Jan 2021 |
Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease
|
|
21 Jan 2021 |
TRIGR Therapeutics and Elpiscience Biopharmaceuticals Announce $117 Million Exclusive China Licensing Transaction for TR009, a Phase 1B Dual Angiogenic Bispecific Antibody Targeting DLL4/VEGF
|
|
21 Jan 2021 |
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
|
|
21 Jan 2021 |
First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
|
